Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-059357
Filing Date
2025-04-28
Accepted
2025-04-28 16:36:51
Documents
71
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q itos-20250331.htm   iXBRL 10-Q 2421750
2 EX-31.1 itos-ex31_1.htm EX-31.1 17399
3 EX-31.2 itos-ex31_2.htm EX-31.2 17403
4 EX-32.1 itos-ex32_1.htm EX-32.1 18199
  Complete submission text file 0000950170-25-059357.txt   9661952

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT itos-20250331.xsd EX-101.SCH 1275750
74 EXTRACTED XBRL INSTANCE DOCUMENT itos-20250331_htm.xml XML 1722416
Mailing Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472
Business Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472 857-204-4583
iTeos Therapeutics, Inc. (Filer) CIK: 0001808865 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39401 | Film No.: 25881003
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)